Structure Therapeutics (NASDAQ:GPCR) Stock Price Up 8%

Structure Therapeutics Inc. (NASDAQ:GPCR) rose 8% during mid-day trading on Thursday . The stock traded as high as $39.33 and last traded at $39.33. Approximately 179,570 shares were traded during trading, a decline of 68% from the average daily volume of 564,966 shares. The stock had previously closed at $36.43.

Analysts Set New Price Targets

GPCR has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Structure Therapeutics in a research note on Thursday, April 18th. Lifesci Capital reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $85.71.

Structure Therapeutics Stock Down 0.1 %

The firm’s 50 day moving average price is $39.66 and its two-hundred day moving average price is $47.81.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Friday, March 8th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. As a group, sell-side analysts forecast that Structure Therapeutics Inc. will post -0.98 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Federated Hermes Inc. raised its position in Structure Therapeutics by 104.2% during the fourth quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock worth $92,411,000 after acquiring an additional 1,157,006 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of Structure Therapeutics by 835.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company’s stock worth $90,752,000 after buying an additional 1,607,525 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Structure Therapeutics by 312.6% during the third quarter. Wellington Management Group LLP now owns 867,579 shares of the company’s stock worth $43,743,000 after buying an additional 657,310 shares in the last quarter. FMR LLC grew its holdings in shares of Structure Therapeutics by 28.5% during the third quarter. FMR LLC now owns 1,590,335 shares of the company’s stock worth $80,185,000 after buying an additional 352,600 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of Structure Therapeutics during the fourth quarter worth about $1,960,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.